达格列净在射血分数中间型或保留型心力衰竭患者的临床应用效果分析  

Analysis of the clinical application effect of Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

作　　者：马超 张清琳 徐晓东[1] 方中[1] 江雪红[1] Ma Chao;Zhang Qinglin;Xu Xiaodong(Department of Cardiology,Chizhou People's Hospital,Chizhou 247000,China)

机构地区：[1]池州市人民医院心血管内科,247000

出　　处：《中华保健医学杂志》2025年第1期58-61,共4页Chinese Journal of Health Care and Medicine

基　　金：安徽省重点研究与开发计划项目(2022e07020058)。

摘　　要：目的分析达格列净在射血分数中间型或保留型心力衰竭患者的临床应用效果。方法选取2022年1月~2023年4月池州市人民医院心血管内科住院的112例射血分数中间型或保留型心力衰竭患者,并随机数表法分为达格列净组(n=54)和对照组(n=58)。两组均予以常规基础治疗,达格列净组每日给予达格列净10 mg。分别比较两组患者左室舒张末内径(LVEDD)、左心室射血分数(LVEF)、B型脑钠肽(BNP)水平治疗前后指标变化情况;分析两组患者出院6个月后发生主要心血管不良事件(MACE)的情况。结果治疗后,达格列净组LVEDD、lgBNP水平分别为(47.74±7.46)mm、(2.41±0.37)mm,均低于对照组的(50.68±7.64)mm、(2.56±0.34)mm;LVEF水平为(56.15±10.83)%,高于对照组(52.50±7.69)%,差异均有统计学意义(t=-2.033、2.020、-2.253,P<0.05)。出院后随访6个月,达格列净组MACE发生率10.71%(6∕56)低于对照组28.57%(16∕56),差异无统计学意义(χ^(2)=5.657,P=0.017)。结论达格列净可改善射血分数中间型或保留型心力衰竭患者临床治疗效果,减少MACE的发生。Objective To evaluate the clinical efficacy of dapagliflozin in patients with heart failure characterized by midrange or preserved ejection fraction.Methods 112 patients with mildly reduced or reserved ejection fraction who were hospitalized in the Department of Cardiology of our hospital from January 2022 to April 2023 were selected as the research objects,and were randomly divided into Dapagliflozin group(n=54)and control group(n=58).Both groups were given routine basic treatment,and Dapagliflozin group was given Dapagliflozin 10 mg daily.Six months after discharge,the changes of left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)and B-type brain natriuretic peptide(BNP)before and after treatment were compared between the two groups.The changes of LVEDD,LVEF and lgBNP in Dapagliflozin group and control group after 6 months of treatment were compared respectively.Finally,the occurrence of(major adverse cardiovascular events)MACE in two groups was analyzed after 6 months of discharge.Results After treatment,the LVEDD and lgBNP levels in the Dapagliflozin group were lower than those in the control group,the LVEF level was higher than that in the control group,with statistical differences(t=-2.033,2.020,-2.253,P<0.05).The incidence of MACE in the Dapagliflozin group was 11.11%lower than that in the control group(27.59%)at 6 months after discharge(χ^(2)=5.657,P=0.017).Conclusion Dapagliflozin can improve the clinical therapeutic effect of patients with intermediate ejection fraction or reserved heart failure,and reduce the occurrence of MACE.

关 键 词：达格列净 射血分数中间型 射血分数保留型 心力衰竭 

分 类 号：R541[医药卫生—心血管疾病]